AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
223.79
+4.77 (2.18%)
Feb 6, 2026, 10:40 AM EST - Market open
AbbVie Revenue
In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth. AbbVie had revenue of $16.62B in the quarter ending December 31, 2025, with 10.04% growth.
Revenue (ttm)
$61.16B
Revenue Growth
+8.57%
P/S Ratio
6.35
Revenue / Employee
$1,112,000
Employees
55,000
Market Cap
395.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
ABBV News
- 1 day ago - AbbVie: The Market Is Getting It Wrong - Seeking Alpha
- 1 day ago - AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot - Seeking Alpha
- 1 day ago - AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise - Seeking Alpha
- 1 day ago - AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake - Seeking Alpha
- 1 day ago - AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade) - Seeking Alpha
- 1 day ago - AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth - Benzinga
- 2 days ago - AbbVie Revenue Rises on Immunology Growth - WSJ